Top

European Archives of Oto-Rhino-Laryngology

Published in:

13-10-2023 | Bevacizumab | Review Article

Intralesional cidofovir vs. bevacizumab for recurrent respiratory papillomatosis: a systematic review and indirect meta-analysis

Authors: Faisal H. Zagzoog, Ahmed M. Mogharbel, Abdulsalam Alqutub, Manal Bukhari, Mohammed I. Almohizea

Published in: European Archives of Oto-Rhino-Laryngology | Issue 2/2024

Abstract

Background

Specific HPV types cause recurrent respiratory papillomatosis (R.R.P.). When administered intralesionally, cidofovir, an antiviral agent, has shown favorable outcomes in reducing papilloma. Bevacizumab, an angiogenesis inhibitor, has demonstrated improved R.R.P. However, both treatments lack FDA approval for R.R.P. Our study aims to evaluate the efficacy and safety of intralesional Cidofovir and Bevacizumab for R.R.P. and compare the two interventions.

Methods

We searched five electronic databases to find relevant studies. After the screening, data were extracted from the included studies. Pooled ratios with 95% confidence intervals (CIs) were used for categorical outcomes, and mean difference (MD) was used for continuous outcomes. Statistical heterogeneity was evaluated using the chi-squared test for I² statistics. The Cochrane Risk of Bias assessment tool was used to assess the methodological quality of randomized controlled trials (RCTs), while the National Institutes of Health's tool was used for observational studies. Analysis was done by Review Manager software.

Results

In our comprehensive meta-analysis of 35 articles involving 836 patients, cidofovir demonstrated an overall remission ratio of (0.90 [95% CI: 0.83, 0.98], p = 0.01), while bevacizumab (0.92 [95% CI: 0.79, 1.07]), p = 0.3). The complete remission ratio for cidofovir was (0.66 [95% CI: 0.57, 0.75], p > 0.0001), while bevacizumab was (0.29 [95% CI: 0.12, 0.71], p = 0.07). In partial remission, Bevacizumab showed a higher ratio than Cidofovir 0.74 [0.55, 0.99] vs. 0.40 [0.30, 0.54]. Bevacizumab had a pooled ratio of 0.07 [95% CI: 0.02, 0.30] in terms of no remission, indicating better outcomes compared to Cidofovir with a ratio of 0.28 [95% CI: 0.16, 0.51]. Additionally, Cidofovir showed a favorable decrease in the Derkay Severity Score (DSS) with a mean difference (MD) of 1.98 [95% CI: 1.44, 2.52].

Conclusion

Cidofovir had a higher impact on complete remission compared to Bevacizumab. Both showed partial remission, with Bevacizumab having a higher ratio. Moreover, Cidofovir showed a significant decrease in DSS. Bevacizumab had lower rates of no remission and recurrence and fewer adverse events compared to Cidofovir. However, the difference between the two treatments was not significant, except for partial remission.

Available only for authorised users

Dickens P, Srivastava G, Loke SL, Larkin S (1991) Human papillomavirus 6, 11, and 16 in laryngeal papillomas. J Pathol 165:243–246. https://doi.org/10.1002/path.1711650308PubMedCrossRef

Ağgünlü L, Erbaş G (2009) Recurrent respiratory papillomatosis with lung involvement. Diagn Interv Radiol 15:93–95PubMed

Larson DA, Derkay CS (2010) Epidemiology of recurrent respiratory papillomatosis. APMIS 118:450–454. https://doi.org/10.1111/j.1600-0463.2010.02619.xPubMedCrossRef

Ivancic R, Iqbal H, DeSilva B, Pan Q, Matrka L (2018) Current and future management of recurrent respiratory papillomatosis. Laryngoscope Investig Otolaryngol 3:22–34. https://doi.org/10.1002/lio2.132PubMedPubMedCentralCrossRef

Rosenberg T, Philipsen BB, Mehlum CS, Dyrvig A-K, Wehberg S, Chirilǎ M et al (2019) Therapeutic use of the human papillomavirus vaccine on recurrent respiratory papillomatosis: a systematic review and meta-analysis. J Infect Dis 219:1016–1025. https://doi.org/10.1093/infdis/jiy616PubMedCrossRef

Mauz PS, Schäfer FA, Iftner T, Gonser P (2018) HPV vaccination as preventive approach for recurrent respiratory papillomatosis—a 22-year retrospective clinical analysis. BMC Infect Dis 18:343. https://doi.org/10.1186/s12879-018-3260-0PubMedPubMedCentralCrossRef

Carifi M, Napolitano D, Morandi M, Dall’Olio D (2015) Recurrent respiratory papillomatosis: current and future perspectives. Ther Clin Risk Manag. https://doi.org/10.2147/TCRM.S81825PubMedPubMedCentralCrossRef

Pransky SM, Albright JT, Magit AE (2003) Long-term follow-up of pediatric recurrent respiratory papillomatosis managed with intralesional cidofovir. Laryngoscope 113:1583–1587. https://doi.org/10.1097/00005537-200309000-00032PubMedCrossRef

Shirley WP, Wiatrak B (2004) Is cidofovir a useful adjunctive therapy for recurrent respiratory papillomatosis in children? Int J Pediatr Otorhinolaryngol 68:413–418. https://doi.org/10.1016/j.ijporl.2003.11.007CrossRef

10.

Akst LM, Lee W, Discolo C, Knott D, Younes A, Koltai PJ (2003) Stepped-dose protocol of cidofovir therapy in recurrent respiratory papillomatosis in children. Arch Otolaryngol Head Neck Surg 129:841–846. https://doi.org/10.1001/archotol.129.8.841PubMedCrossRef

11.

Lee AS, Rosen CA (2004) Efficacy of cidofovir injection for the treatment of recurrent respiratory papillomatosis. J Voice 18:551–556. https://doi.org/10.1016/j.jvoice.2003.07.007PubMedCrossRef

12.

Sidell DR, Nassar M, Cotton RT, Zeitels SM, De Alarcon A (2014) High-dose sublesional bevacizumab (avastin) for pediatric recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 123:214–221. https://doi.org/10.1177/0003489414522977PubMedCrossRef

13.

Zeitels SM, Barbu AM, Landau-Zemer T, Lopez-Guerra G, Burns JA, Friedman AD et al (2011) Local injection of bevacizumab (Avastin) and angiolytic KTP laser treatment of recurrent respiratory papillomatosis of the vocal folds: a prospective study. Ann Otol Rhinol Laryngol 120:627–634. https://doi.org/10.1177/000348941112001001PubMedCrossRef

14.

Rogers DJ, Ojha S, Maurer R, Hartnick CJ (2013) Use of adjuvant intralesional bevacizumab for aggressive respiratory papillomatosis in children. JAMA Otolaryngol Head Neck Surg 139:496–501. https://doi.org/10.1001/jamaoto.2013.1810PubMedCrossRef

15.

Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (2019) Cochrane handbook for systematic reviews of interventions. https://doi.org/10.1002/9781119536604

16.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, The PRISMA et al (2020) statement: an updated guideline for reporting systematic reviews. BMJ 2021:n71. https://doi.org/10.1136/bmj.n71CrossRef

17.

Institution NH. https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools n.d. Accessed 25 May 2023

18.

Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ [Internet] n.d.

19.

The Cochrane Collaboration 2020. Review Manager (RevMan) [Computer program]. Version 5.4. n.d.

20.

Manzini M, Becker CF, Schweiger C, Manica D, Kuhl G (2014) Use of adjuvant bevacizumab for the treatment of recurrent respiratory papillomatosis: experience with five cases. Int Arch Otorhinolaryngol 18(S 01):a2439CrossRef

21.

Ablanedo-Terrazas Y, Soda-Merhy A, Hernández-Palestina M, Ormsby CE, Reyes TG (2012) Intralesional cidofovir in severe juvenile respiratory papillomatosis. B-ENT 8:197–202PubMed

22.

Hall SR, Thiriveedi M, Yandrapalli U, Zhang N, Lott DG (2021) Sublesional bevacizumab injection for recurrent respiratory papillomatosis: evaluation of utility in a typical clinical practice. Ann Otol Rhinol Laryngol 130:1164–1170. https://doi.org/10.1177/0003489421998215PubMedCrossRef

23.

Hoesli RC, Thatcher AL, Hogikyan ND, Kupfer RA (2020) Evaluation of safety of intralesional cidofovir for adjuvant treatment of recurrent respiratory papillomatosis. JAMA Otolaryngol Head Neck Surg 146:231–236. https://doi.org/10.1001/jamaoto.2019.4029PubMedPubMedCentralCrossRef

24.

McMurray JS, Connor N, Ford CN (2008) Cidofovir efficacy in recurrent respiratory papillomatosis: a randomized, double-blind, placebo-controlled study. Ann Otol Rhinol Laryngol 117:477–483. https://doi.org/10.1177/000348940811700702PubMedCrossRef

25.

Meacham RK, Thompson JW (2017) Comparison of cidofovir and the measles, mumps, and rubella vaccine in the treatment of recurrent respiratory papillomatosis. Ear, Nose Throat J 96:69–74. https://doi.org/10.1177/014556131709600209PubMedCrossRef

26.

Mikolajczak S, Quante G, Weissenborn S, Wafaisade A, Wieland U, Lüers JC et al (2012) The impact of cidofovir treatment on viral loads in adult recurrent respiratory papillomatosis. Eur Arch Oto-Rhino-Laryngol 269:2543–2548. https://doi.org/10.1007/s00405-012-2103-7CrossRef

27.

Murono S, Nakanishi Y, Tsuji A, Endo K, Kondo S, Wakisaka N et al (2016) Intralesional cidofovir injection for recurrent respiratory papillomatosis in Japan. Auris Nasus Larynx 43:541–545. https://doi.org/10.1016/j.anl.2016.01.005PubMedCrossRef

28.

Naiman AN, Ayari S, Nicollas R, Landry G, Colombeau B, Froehlich P (2006) Intermediate-term and long-term results after treatment by cidofovir and excision in juvenile laryngeal papillomatosis. Ann Otol Rhinol Laryngol 115:667–672. https://doi.org/10.1177/000348940611500903PubMedCrossRef

29.

Naiman AN, Ceruse P, Coulombeau B, Froehlich P (2003) Intralesional cidofovir and surgical excision for laryngeal papillomatosis. Laryngoscope 113:2174–2181. https://doi.org/10.1097/00005537-200312000-00024PubMedCrossRef

30.

Avelino MA, Gutzman RL, Fujita RR, Pignatari S, Weckx LL, Pontes P. Cidofovir effects on recurrent laryngeal papillomatosis in children: preliminary report. Revista Brasileira de Otorrinolaringologia. 2004;70:734-8.CrossRef

31.

Ablanedo-Terrazas Y, Estrada-Camacho O, Alvarado-de la Barrera C, Ramírez-García A, Tona-Acedo G, Bross-Soriano D et al (2022) Efficacy of cidofovir versus bevacizumab in recurrent respiratory papillomatosis: A randomized, double-blind, placebo-controlled pilot study. Acta Otorrinolaringol (English Ed) 73:82–88. https://doi.org/10.1016/j.otoeng.2020.12.001CrossRef

32.

Pontes P, Avelino M, Pignatari S, Weckx LLM (2006) Effect of local application of cidofovir on the control of recurrences in recurrent laryngeal papillomatosis. Otolaryngol - Head Neck Surg 135:22–27. https://doi.org/10.1016/j.otohns.2005.10.060PubMedCrossRef

33.

Pontes P, Weckx LLM, Pignatari SSN, Fujita RR, Avelino MAG, Sato J (2009) Local application of ci dofovir as adjuvant therapy in recurrent laryngeal papillomatosis in children. Rev Assoc Med Bras 55:581–586. https://doi.org/10.1590/s0104-42302009000500023PubMedCrossRef

34.

Pransky SM, Brewster DF, Magit AE, Kearus DB (2000) Clinical update on 10 children treated with intralesional cidofovir injections for severe recurrent respiratory papillomatosis. Arch Otolaryngol Head Neck Surg 126:1239–1243. https://doi.org/10.1001/archotol.126.10.1239PubMedCrossRef

35.

Pudszuhn A, Welzel C, Bloching M, Neumann K (2007) Intralesional Cidofovir application in recurrent laryngeal papillomatosis. Eur Arch Oto-Rhino-Laryngol 264:63–70. https://doi.org/10.1007/s00405-006-0151-6CrossRef

36.

Sappington J, Eisenbeis JF (2009) The effect of cidofovir injection concurrent with surgical resection for adult onset recurrent respiratory papillomatosis. Laryngoscope 119:96. https://doi.org/10.1002/lary.20388CrossRef

37.

Shemen LJ, Shnayder Y (2006) Office-based intralesional cidofovir injections for nasal septal papilloma: A pilot study. Otolaryngol - Head Neck Surg 135:149–151. https://doi.org/10.1016/j.otohns.2005.12.028PubMedCrossRef

38.

Snoeck R, Wellens W, Desloovere C, Van Ranst M, Naesens L, De Clercq E et al (1998) Treatment of severe laryngeal papillomatosis with intralesional injections of cidofovir [(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine]. J Med Virol 54:219–225. https://doi.org/10.1002/(SICI)1096-9071(199803)54:3%3c219::AID-JMV13%3e3.0.CO;2-CPubMedCrossRef

39.

Tanna N, Sidell D, Joshi AS, Bielamowicz SA (2008) Adult intralesional cidofovir therapy for laryngeal papilloma: a 10-year perspective. Arch Otolaryngol - Head Neck Surg 134:497–500. https://doi.org/10.1001/archotol.134.5.497PubMedCrossRef

40.

Tjon Pian Gi REA, Ilmarinen T, Van Den Heuvel ER, Aaltonen LM, Andersen J, Brunings JW, et al. Safety of intralesional cidofovir in patients with recurrent respiratory papillomatosis: An international retrospective study on 635 RRP patients. Eur Arch Oto-Rhino-Laryngology 2013;270:1679–87. https://doi.org/10.1007/s00405-013-2358-7.

41.

Valera F, Maldonato L, Lima J, Küpper DS, Lacerda RN, Mamede R et al (2010) Efficacy of cidofovir in recurrent juvenile respiratory papillomatosis. Braz J Otorhinolaryngol 76:713–717. https://doi.org/10.1590/s1808-86942010000600008PubMedCrossRef

42.

Verguts MML, Genbrugge E, De Jong FICRS (2009) Treatment results in adult-onset recurrent respiratory papillomatosis. B-ENT 5:137–141PubMed

43.

Wierzbicka M, Jackowska J, Bartochowska A, Józefiak A, Szyfter W, Kȩdzia W (2011) Effectiveness of cidofovir intralesional treatment in recurrent respiratory papillomatosis. Eur Arch Oto-Rhino-Laryngology 268:1305–1311. https://doi.org/10.1007/s00405-011-1599-6CrossRef

44.

Best SR, Friedman AD, Landau-Zemer T, Barbu AM, Burns JA, Freeman MW et al (2012) Safety and dosing of bevacizumab (Avastin) for the treatment of recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 121:587–593. https://doi.org/10.1177/000348941212100905PubMedCrossRef

45.

Bielamowicz S, Villagomez V, Stager SV, Wilson WR (2002) Intralesional cidofovir therapy for laryngeal papilloma in an adult cohort. Laryngoscope 112:696–699. https://doi.org/10.1097/00005537-200204000-00019PubMedCrossRef

46.

Chung BJ, Akst LM, Koltai PJ (2006) 3.5-Year follow-up of intralesional cidofovir protocol for pediatric recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol 70:1911–1917. https://doi.org/10.1016/j.ijporl.2006.06.018PubMedCrossRef

47.

Co J, Woo P (2004) Serial office-based intralesional injection of cidofovir in adult-onset recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 113:859–862. https://doi.org/10.1177/000348940411301102PubMedCrossRef

48.

Dikkers FG (2006) Treatment of recurrent respiratory papillomatosis with microsurgery in combination with intralesional cidofovir—a prospective study. Eur Arch Oto-Rhino-Laryngology 263:440–443. https://doi.org/10.1007/s00405-005-1013-3CrossRef

49.

Grasso M, Remacle M, Bachy V, Van Der Vorst S, Lawson G (2014) Use of cidofovir in HPV patients with recurrent respiratory papillomatosis. Eur Arch Oto-Rhino-Laryngology 271:2983–2990. https://doi.org/10.1007/s00405-014-3055-xCrossRef

50.

Derkay CS, Bluher AE (2018) Recurrent respiratory papillomatosis: update 2018. Curr Opin Otolaryngol Head Neck Surg 26:421–425. https://doi.org/10.1097/MOO.0000000000000490PubMedCrossRef

51.

Graupp M, Gugatschka M, Kiesler K, Reckenzaun E, Hammer G, Friedrich G (2013) Experience of 11 years use of cidofovir in recurrent respiratory papillomatosis. Eur Arch Oto-Rhino-Laryngology 270:641–646. https://doi.org/10.1007/s00405-012-2221-2CrossRef

52.

Lalezari JP (1997) Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. Ann Intern Med 126:257. https://doi.org/10.7326/0003-4819-126-4-199702150-00001PubMedCrossRef

53.

Thomson PD (2003) Physicians’ desk reference. In: Physicians’ desk reference 2003, pp 3550–3550

54.

Wemer RD, Lee JH, Hoffman HT, Robinson RA, Smith RJH (2005) Case of progressive dysplasia concomitant with intralesional cidofovir administration for recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol 114:836–839. https://doi.org/10.1177/000348940511401105PubMedCrossRef

55.

Lott DG, Krakovitz PR (2009) Squamous cell carcinoma associated with intralesional injection of cidofovir for recurrent respiratory papillomatosis. Laryngoscope 119:567–570. https://doi.org/10.1002/lary.20082PubMedCrossRef

56.

Bayan S, Faquin WC, Zeitels SM (2019) Glottic carcinoma in young patients. Ann Otol Rhinol Laryngol 128:25S-32S. https://doi.org/10.1177/0003489418818852PubMedCrossRef

57.

Chhetri DK, Blumin JH, Shapiro NL, Berke GS (2002) Office-based treatment of laryngeal papillomatosis with percutaneous injection of cidofovir. Otolaryngol Neck Surg 126:642–648. https://doi.org/10.1067/mhn.2002.125604CrossRef

58.

Fusconi M, Grasso M, Greco A, Gallo A, Campo F, Remacle M et al (2014) Recurrent respiratory papillomatosis by HPV: review of the literature and update on the use of cidofovir. Acta Otorhinolaryngol Ital 34:375–381PubMedPubMedCentral

59.

Zeitels SM, Lopez-Guerra G, Burns JA, Lutch M, Friedman AM, Hillman RE (2009) Microlaryngoscopic and office-based injection of bevacizumab (Avastin) to enhance 532-nm pulsed KTP laser treatment of glottal papillomatosis. Ann Otol Rhinol Laryngol 118:1–24. https://doi.org/10.1177/000348940911800901CrossRef

Title: Intralesional cidofovir vs. bevacizumab for recurrent respiratory papillomatosis: a systematic review and indirect meta-analysis
Authors: Faisal H. Zagzoog
Ahmed M. Mogharbel
Abdulsalam Alqutub
Manal Bukhari
Mohammed I. Almohizea
Publication date: 13-10-2023
Publisher: Springer Berlin Heidelberg
Keywords: Bevacizumab
Antiviral Agents
Human Papillomavirus
Published in: European Archives of Oto-Rhino-Laryngology / Issue 2/2024
Print ISSN: 0937-4477
Electronic ISSN: 1434-4726
DOI: https://doi.org/10.1007/s00405-023-08279-0

At a glance: The STEP trials

Springer Medicine

Intralesional cidofovir vs. bevacizumab for recurrent respiratory papillomatosis: a systematic review and indirect meta-analysis

Abstract

Background

Methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 2/2024

Inverted clip technique for cochlear implant electrode array fixation: how I do it

Effectiveness of temperature-controlled radiofrequency neurolysis of the posterior nasal nerve to treat chronic rhinitis: a systematic review and meta-analysis

Post-operative radiotherapy in adenoid cystic carcinoma of salivary glands versus surgery alone: what is the evidence about survival and local control? A systematic review and meta-analysis

Is artificial intelligence ready to replace specialist doctors entirely? ENT specialists vs ChatGPT: 1-0, ball at the center

Does skin prick test response intensity predict symptom severity and efficacy of subcutaneous immunotherapy in allergic rhinitis?

Examining otolaryngologists’ attitudes towards large language models (LLMs) such as ChatGPT: a comprehensive deep learning analysis